InMode Ltd. designs, develops, manufactures, and markets minimally-invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies. The company offers minimally-invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments. It also designs, develops, manufactures, and markets non-invasive medical aesthetic products that target an array of procedures, including permanent hair reduction, facial skin rejuvenation, wrinkle reduction, cellulite treatment, skin appearance and texture, and superficial benign vascular and pigmented lesions, as well as hands-free medical aesthetic products that target a range of procedures, such as skin tightening, fat reduction, and muscle stimulation. InMode Ltd. offers its products directly in United States, Canada, United Kingdom, Spain, India, Australia, and France, as well as through distributors in 47 countries. The company was formerly known as Invasix Ltd. and changed its name to InMode Ltd. in November 2017. InMode Ltd. was founded in 2008 and is headquartered in Yokneam, Israel.
IPO Year: 2019
Exchange: NASDAQ
Website: inmodemd.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/29/2025 | Buy → Neutral | BTIG Research | |
| 4/28/2025 | $22.00 → $16.00 | Outperform → Neutral | Robert W. Baird |
| 10/17/2024 | $25.00 | Buy | BTIG Research |
| 7/23/2024 | $21.00 → $19.00 | Buy → Hold | Jefferies |
| 11/3/2023 | $52.00 → $24.00 | Buy → Neutral | UBS |
| 10/13/2023 | $55.00 → $22.00 | Buy → Hold | Canaccord Genuity |
| 3/29/2023 | $40.00 | Buy | UBS |
| 2/17/2023 | Buy → Hold | Needham | |
| 12/21/2022 | $44.00 | Overweight | Barclays |
| 10/12/2022 | $40.00 | Buy | Jefferies |
6-K - InMode Ltd. (0001742692) (Filer)
6-K - InMode Ltd. (0001742692) (Filer)
6-K - InMode Ltd. (0001742692) (Filer)
6-K - InMode Ltd. (0001742692) (Filer)
6-K - InMode Ltd. (0001742692) (Filer)
6-K - InMode Ltd. (0001742692) (Filer)
6-K/A - InMode Ltd. (0001742692) (Filer)
S-8 - InMode Ltd. (0001742692) (Filer)
20-F - InMode Ltd. (0001742692) (Filer)
6-K - InMode Ltd. (0001742692) (Filer)
Fastest customizable press release news feed in the world
YOKNEAM, Israel, Nov. 5, 2025 /PRNewswire/ -- InMode Ltd. (NASDAQ:INMD) ("InMode"), a leading global provider of innovative medical technologies, today announced its consolidated financial results for the third quarter ended September 30, 2025. Third Quarter 2025 Highlights: Quarterly GAAP revenues of $93.2 million, compared to $130.2 million in the third quarter of 2024, which included $31.9 million of pre-order sales.Quarterly revenues from consumables and service of $19.9 million, an increase of 26% compared to the third quarter of 2024.GAAP operating income of $20.9 million. *Non-GAAP operating income was $23.6 million.Total cash position of $532.3 million as of September 30, 2025, incl
IRVINE, Calif., Nov. 3, 2025 /PRNewswire/ -- InMode Ltd. (NASDAQ:INMD), a leading global provider of innovative medical technologies, has appointed Michael Dennison, most recently Vice President of Sales, as President of North America. Dennison has held nearly every sales position in the aesthetic medical device industry, consistently producing at the highest level in each. With close to a decade of leadership experience at InMode, Dennison has advanced through roles from District Sales Manager to Vice President of Sales, driving national revenue growth, expanding market shar
YOKNEAM, Israel, Oct. 30, 2025 /PRNewswire/ -- InMode Ltd. (NASDAQ:INMD), a leading global provider of innovative medical technologies, today announced the participation in the following investor conferences in November: UBS Global Healthcare Conference Presenter: Yair Malca, Chief Financial Officer Format: In-person one-on-one meetings Location: Palm Beach Gardens, FL When: Monday, November 10 Jefferies Global Healthcare Conference Presenter: Moshe Mizrahy, Chief Executive Officer Format: In-person fireside chat moderated by Matt Taylor, Senior Equity Analyst, and one-on-one meetings Location: London, U.K. When: Tuesday, November 18, Fireside Chat at 4:00 pm GMT A live webcast of the prese
Conference call to be held on Wednesday, November 5, 2025, at 8:30 a.m. Eastern Time YOKNEAM, Israel, Oct. 9, 2025 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, announced today that it expects to release its financial results for the third quarter 2025 before the Nasdaq market opens on Wednesday, November 5, 2025. InMode is currently finalizing its financial results for the third quarter of 2025. While complete financial information and operating data are not yet available, set forth below are certain preliminary results of InMode's financial results for such period, subject to final adjustments and other developments that may aris
Believes the Board Should Approve and Execute a 10% Buyback in Q4 2025 and Another 10% Buyback in Q1 2026 Maintains Board Has Legal and Fiduciary Duty to Act in Best Interests of Shareholders MIAMI, Sept. 9, 2025 /PRNewswire/ -- DOMA Perpetual Capital Management LLC, a significant stockholder of InMode Ltd. (NYSE: INMD) ("InMode"), today sent a letter to the Board of Directors of InMode (the "Board") urging the Board to return capital to shareholders. The letter can be downloaded here The full text of the letter follows: September 9th, 2025 To the Board Members of InMode: In
YOKNEAM, Israel, Sept. 2, 2025 /PRNewswire/ -- InMode Ltd. (NASDAQ:INMD), a leading global provider of innovative medical technologies, today announced that Yair Malca, Chief Financial Officer will present in-person at the Baird 2025 Global Healthcare Conference in New York on Sept. 10, 2025. The fireside chat, moderated by Jeff Johnson, Senior Research Analyst, is scheduled for 8:30 am Eastern Time on Wednesday, Sept. 10, and a live webcast of the presentation can be accessed here. InMode will also hold one-on-one investor meetings in person that same day. To schedule a meeting, please contact your Baird representative. For more information about the event, visit InMode's investor relatio
YOKNEAM, Israel, Aug. 5, 2025 /PRNewswire/ -- InMode Ltd. (NASDAQ:INMD), a leading global provider of innovative medical technologies, today announced the participation in the following investor conferences in August: 10th Annual Needham Virtual MedTech & Diagnostics Conference Presenters: Moshe Mizrahy, Chief Executive Officer Format: Virtual one-on-one meetings When: Monday, Aug. 11 Canaccord 45th Annual Global Growth Conference Presenters: Yair Malca, Chief Financial Officer Format: In-person fireside chat moderated by Caitlin Cronin, Director of MedTech Equity Research, and meetings When: Tuesday, Aug. 12 at 2:30 pm ET A live webcast of the presentation can be accessed here. Location:
YOKNEAM, Israel, July 30, 2025 /PRNewswire/ -- InMode Ltd. (NASDAQ:INMD) ("InMode"), a leading global provider of innovative medical technologies, today announced its consolidated financial results for the second quarter ended June 30, 2025. Second Quarter 2025 Highlights: Quarterly GAAP revenues of $95.6 million, compared to $86.4 million in the second quarter of 2024.Quarterly revenues from consumables and service of $19.8 million, a decrease of 6% compared to the second quarter of 2024.GAAP operating income of $22.9 million, *non-GAAP operating income of $26.3 million.Total cash position of $510.7 million as of June 30, 2025, including cash and cash equivalents, marketable securities and
Conference call to be held on Wednesday, July 30, 2025, at 8:30 a.m. Eastern Time YOKNEAM, Israel, July 10, 2025 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, announced today that it expects to release its financial results for the second quarter 2025 before the Nasdaq market opens on Wednesday, July 30, 2025. InMode is currently finalizing its financial results for the second quarter of 2025. While complete financial information and operating data are not yet available, set forth below are certain preliminary results of InMode's financial results for such period, subject to final adjustments and other developments that may arise b
YOKNEAM, Israel, May 28, 2025 /PRNewswire/ -- InMode Ltd. (NASDAQ:INMD) ("InMode"), a leading global provider of innovative medical technologies, today sent a letter to DOMA Perpetual Capital Management LLC ("DOMA") CEO and CIO Pedro Escudero in response to issues presented in his public letter dated May 9, 2025. The letter can be viewed here The full text of the letter follows: May 28, 2025 Mr. Pedro EscuderoCEO and CIODOMA, Perpetual Capital Management LLC Dear Mr. Escudero, This letter is in response to your letter dated May 9, 2025. First, I would like to thank you for voting for me to be re-elected to the Board of Directors. I really appreciate your vote of confidence and trust. I unde
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
BTIG Research downgraded InMode from Buy to Neutral
Robert W. Baird downgraded InMode from Outperform to Neutral and set a new price target of $16.00 from $22.00 previously
BTIG Research initiated coverage of InMode with a rating of Buy and set a new price target of $25.00
Jefferies downgraded InMode from Buy to Hold and set a new price target of $19.00 from $21.00 previously
UBS downgraded InMode from Buy to Neutral and set a new price target of $24.00 from $52.00 previously
Canaccord Genuity downgraded InMode from Buy to Hold and set a new price target of $22.00 from $55.00 previously
UBS initiated coverage of InMode with a rating of Buy and set a new price target of $40.00
Needham downgraded InMode from Buy to Hold
Barclays initiated coverage of InMode with a rating of Overweight and set a new price target of $44.00
Jefferies initiated coverage of InMode with a rating of Buy and set a new price target of $40.00
Live Leadership Updates
IRVINE, Calif., Nov. 3, 2025 /PRNewswire/ -- InMode Ltd. (NASDAQ:INMD), a leading global provider of innovative medical technologies, has appointed Michael Dennison, most recently Vice President of Sales, as President of North America. Dennison has held nearly every sales position in the aesthetic medical device industry, consistently producing at the highest level in each. With close to a decade of leadership experience at InMode, Dennison has advanced through roles from District Sales Manager to Vice President of Sales, driving national revenue growth, expanding market shar
Live finance-specific insights
YOKNEAM, Israel, Nov. 5, 2025 /PRNewswire/ -- InMode Ltd. (NASDAQ:INMD) ("InMode"), a leading global provider of innovative medical technologies, today announced its consolidated financial results for the third quarter ended September 30, 2025. Third Quarter 2025 Highlights: Quarterly GAAP revenues of $93.2 million, compared to $130.2 million in the third quarter of 2024, which included $31.9 million of pre-order sales.Quarterly revenues from consumables and service of $19.9 million, an increase of 26% compared to the third quarter of 2024.GAAP operating income of $20.9 million. *Non-GAAP operating income was $23.6 million.Total cash position of $532.3 million as of September 30, 2025, incl
Conference call to be held on Wednesday, November 5, 2025, at 8:30 a.m. Eastern Time YOKNEAM, Israel, Oct. 9, 2025 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, announced today that it expects to release its financial results for the third quarter 2025 before the Nasdaq market opens on Wednesday, November 5, 2025. InMode is currently finalizing its financial results for the third quarter of 2025. While complete financial information and operating data are not yet available, set forth below are certain preliminary results of InMode's financial results for such period, subject to final adjustments and other developments that may aris
Believes the Board Should Approve and Execute a 10% Buyback in Q4 2025 and Another 10% Buyback in Q1 2026 Maintains Board Has Legal and Fiduciary Duty to Act in Best Interests of Shareholders MIAMI, Sept. 9, 2025 /PRNewswire/ -- DOMA Perpetual Capital Management LLC, a significant stockholder of InMode Ltd. (NYSE: INMD) ("InMode"), today sent a letter to the Board of Directors of InMode (the "Board") urging the Board to return capital to shareholders. The letter can be downloaded here The full text of the letter follows: September 9th, 2025 To the Board Members of InMode: In
YOKNEAM, Israel, July 30, 2025 /PRNewswire/ -- InMode Ltd. (NASDAQ:INMD) ("InMode"), a leading global provider of innovative medical technologies, today announced its consolidated financial results for the second quarter ended June 30, 2025. Second Quarter 2025 Highlights: Quarterly GAAP revenues of $95.6 million, compared to $86.4 million in the second quarter of 2024.Quarterly revenues from consumables and service of $19.8 million, a decrease of 6% compared to the second quarter of 2024.GAAP operating income of $22.9 million, *non-GAAP operating income of $26.3 million.Total cash position of $510.7 million as of June 30, 2025, including cash and cash equivalents, marketable securities and
Conference call to be held on Wednesday, July 30, 2025, at 8:30 a.m. Eastern Time YOKNEAM, Israel, July 10, 2025 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, announced today that it expects to release its financial results for the second quarter 2025 before the Nasdaq market opens on Wednesday, July 30, 2025. InMode is currently finalizing its financial results for the second quarter of 2025. While complete financial information and operating data are not yet available, set forth below are certain preliminary results of InMode's financial results for such period, subject to final adjustments and other developments that may arise b
Believes the Board Should Immediately Resume and Accelerate Buybacks Asserts Board Should Remove Moshe Mizrahy as CEO of the Company MIAMI, May 9, 2025 /PRNewswire/ -- DOMA Perpetual Capital Management LLC, a significant stockholder of InMode Ltd. (NYSE: INMD) ("InMode"), today sent a letter to the Board of Directors of InMode (the "Board") urging the Board to continue its stock repurchase program and to replace its CEO. The letter can be downloaded here The full text of the letter follows: May 9th, 2025 To the Board Members of InMode: For over a year, we have communicated p
In April 2025, Completed Recent Share Repurchase Program of 6.95 Million Shares YOKNEAM, Israel, April 28, 2025 /PRNewswire/ -- InMode Ltd. (NASDAQ:INMD) ("InMode"), a leading global provider of innovative medical technologies, today announced its consolidated financial results for the first quarter ended March 31, 2025. First Quarter 2025 Highlights: Quarterly GAAP revenues of $77.9 million, compared to $80.3 million in the first quarter of 2024.Quarterly revenues from consumables and service of $20.2 million, a decrease of 10% compared to the first quarter of 2024.GAAP operating income of $15.6 million, *non-GAAP operating income of $18.1 million.Total cash position of $512.9 million as
Conference call to be held on Monday, April 28, 2025, at 8:30 a.m. Eastern Time YOKNEAM, Israel, April 14, 2025 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, announced today that it expects to release its financial results for the first quarter 2025 before the Nasdaq market opens on Monday, April 28, 2025. InMode is currently finalizing its financial results for the first quarter of 2025. While complete financial information and operating data are not yet available, set forth below are certain preliminary results of I
Clarifies Capital Allocation Strategy and Commitment to Shareholder Returns Refutes Misconceptions on Staffing and Production Asserts No Justification for Additional Legal Action YOKNEAM, Israel, March 6, 2025 /PRNewswire/ -- InMode Ltd. (NASDAQ:INMD) ("InMode"), a leading global provider of innovative medical technologies, today sent a letter to DOMA Perpetual Capital Management LLC ("DOMA") CEO and CIO Pedro Escudero in response to issues presented in his public letter dated January 15, 2025. The letter can be viewed here The full text of the letter follows: March 6, 2025 Mr. Pedro EscuderoCEO and CIODOMA Perpetual Capital Management LLC Dear Mr. Escudero, As CEO of InMode, I felt it was
Quarterly GAAP revenues of $97.9 million and full year revenue of $394.8 million Returned $285.4 million of capital to shareholders in full year 2024 Together with new 10% program, represents repurchase of approximately 27% of shares outstanding within 15 month timeframe, with the potential of substantial additional capital return in 2025 YOKNEAM, Israel, Feb. 4, 2025 /PRNewswire/ -- InMode Ltd. (NASDAQ:INMD) ("InMode"), a leading global provider of innovative medical technologies, today announced its consolidated financial results for the fourth quarter and full year 2024. F
This live feed shows all institutional transactions in real time.
SC 13G/A - InMode Ltd. (0001742692) (Subject)
SC 13G/A - InMode Ltd. (0001742692) (Subject)
SC 13G - InMode Ltd. (0001742692) (Subject)
SC 13G/A - InMode Ltd. (0001742692) (Subject)
SC 13G/A - InMode Ltd. (0001742692) (Subject)